Please login to the form below
kinase inhibitor
This page shows the latest kinase inhibitor news and features for those working in and with pharma, biotech and healthcare.
Eli Lilly’s Jaypirca granted FDA accelerated approval for non-Hodgkin lymphomas
Eli Lilly’s non-covalent Bruton's tyrosine kinase (BTK) inhibitor Jaypirca (pirtobrutinib) has been granted accelerated approval by the US Food and Drug Administration (FDA) to treat a subset of ... have received at least two lines of therapy,
Latest news
-
Bristol Myers Squibb's lung cancer drug Augtyro receives FDA approval
Augtyro, which is a tyrosine kinase inhibitor (TKI) designed to minimise interactions that can lead to certain forms of treatment resistance in ROS1-positive metastatic NSCLC patients, was added to BMS’ ... The FDA’s decision on Augtyro comes just
-
Pfizer’s Litfulo approved by MHRA for adults and adolescents with alopecia areata
Litfulo, which is a one-daily oral kinase inhibitor, works by blocking the activity of enzymes in the body involved in inflammation at the hair follicle.
-
Roche announces positive phase 3 results for Alecensa in early-stage lung cancer
Roche has shared new results from a late-stage study of its anaplastic lymphoma kinase (ALK) inhibitor Alecensa (alectinib) in early-stage lung cancer.
-
Pfizer’s Litfulo approved by EC for adults and adolescents with severe alopecia areata
Litfulo, which is a one-daily oral kinase inhibitor, works by blocking the activity of signalling molecules and immune cells believed to contribute to the loss of hair in patients with
-
AstraZeneca shares positive phase 3 results for Tagrisso combination in lung cancer
NSCLC) to receive the Tagrisso/chemotherapy combination or the EGFR-tyrosine kinase inhibitor alone. ... Approximately 10% to 15% of NSCLC patients in the US and Europe have EGFRm NSCLC, with this patient population particularly sensitive to treatment
More from news
Approximately 0 fully matching, plus 240 partially matching documents found.
Latest Intelligence
-
AI: the smart money is on the smart thinking
Using machine learning, a small team of four researchers were able to identify an initial 370 kinase inhibitors, and then quickly narrow this down to the six most likely to work – ... Using GENTRL, the company was able to design a novel DDR1 kinase
-
Can protein degraders unlock ‘undruggable’ drug targets?
Some groups are focusing on SNIPERs – an acronym for Specific and Non-genetic Inhibitor of apoptosis protein-dependent Protein Erasers. – ... These compounds could be used to tackle resistance to kinase inhibitor drugs, for example.
-
Deal Watch January 2018
Acquisition company - remaining 90%. 9, 000. Impact Biomedicines/ Celgene. Fedratinib, highly selective JAK2 kinase inhibitor for myelofibrosis (p3) and polycythemia vera. ... This acquisition brings tucatinib, an oral tyrosine kinase inhibitor that is
-
Deal Watch September 2016
No financial terms were disclosed. Genentech signed an exclusive licence [global excluding South Korea] with Hanmi Pharmaceutical to develop and market HM95573, a pan-RAF inhibitor. ... 1, 000+. Hanmi / Genentech. Licence. HM95573, a selective
-
Deal Watch June 2016
acquisition assets. 350. CrystalGenomics/ Aptose Biosciences. CG026806 inhibitor of Bruton's tyrosine kinase, FMS-like tyrosine kinase 3 and Aurora kinases (preclinical). † ... acquisition company. 105. Nektar Therapeutics/ Daiichi Sankyo Europe.
More from intelligence
Approximately 0 fully matching, plus 20 partially matching documents found.
Latest appointments
-
AZ appoints Susan Galbraith as executive vice president, oncology R&D
This includes PARP inhibitor Lynparza (olaparib), third-generation tyrosine kinase inhibitor (TKI) Tagrisso (osimertinib), the recently approved MET inhibitor Orpathys (savolitinib) and Koselugo (selumetinib) – indicated for the treatment of
-
Akinion appoints Dr Richard Jones as CEO
In his new role at Akinion Pharmaceuticals Dr Jones will oversee a company focused on acute myeloid leukaemia and its lead candidate drug AKN-028, a small molecule kinase inhibitor currently
-
Creabilis names Catherine Moukheibir as chairman of the board
Moukheiber will head the board as it progresses its lead product CT327, a first-in-class selective TrkA kinase inhibitor for the treatment of pruritus (itching) due to psoriasis.
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
- HCP ENGAGEMENT STUDY: Pharma shifts top priority to HCP insights and impact metrics
- AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer
- BMS shares positive phase 3 results for Opdivo/Yervoy combination in colorectal cancer
- Stanford Medicine researchers find blood tests help predict organ failure
- GSK and GCOA report reveals global inequities in adult immunisation uptake
- A “Leaky Pipeline” and the Loss of Talented Female Physicians
No results were found
PMHub
Videum Health
Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...
Latest intelligence
- Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
- ...
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
